Agios Pharmaceuticals (AGIO) announced its anticipated key 2025 milestones and value-driving catalysts through 2026. FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia; PDUFA Goal Date is September 7, 2025. Topline Results from Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease to be Announced in Late 2025, with Potential U.S. Commercial Launch in 2026. Strong Financial Position Provides Opportunity to Maximize Potential PYRUKYND Commercial Launches, Advance Early- and Mid-Stage Clinical Programs and Expand Pipelin.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals announces FDA accepted sNDA for PYRUKYND
- Agios Pharmaceuticals price target lowered to $55 from $60 at BofA
- Agios Pharmaceuticals announces EC adopted positive decision for mitapivat
- Biotech Alert: Searches spiking for these stocks today
- Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank